Talented Women at Every Level of Nephrology

Talented Women at Every Level of Nephrology

A glance at the website for the division of nephrology brings a short paragraph into focus. It includes these three sentences, which could easily be considered a vision statement: “We are devoted to training the next generation of nephrologists in a supportive environment that cultivates their individual passions. We are dedicated to creating and maintaining a diverse and inclusive community. We are Stanford Nephrology.”

A New Division Chief

When associate professor Tara Chang, MD, MS, assumed the position of chief of the division of nephrology in early 2021, she was following directly in the footsteps of her mentor, Glenn Chertow, MD, MPH. Chang has only good things to say about Chertow: “He had a critical role in shaping my career. And it’s really through his efforts that our division is so diverse with regard to women and with regard to race and ethnicity, both at the faculty level and at the fellowship level.”

Tara Chang, MD, MS

Tara Chang, MD, MS

The way Chang ended up with nephrology as her specialty reflects her approach to many things: “I was never one of those people who had a grand plan for life. Opportunities arose and I took them as they came. As an example, UC-San Francisco wasn’t actually my first choice for residency but matching there changed my trajectory. I met fantastic faculty in nephrology there, so I decided to specialize in this field.”

Her research program covers almost everyone with kidney disease, which has a great deal of overlap with cardiovascular disease. Chronic kidney disease is a risk factor for many cardiovascular diseases, including premature coronary disease, hypertension, and atrial fibrillation. “What has been cool in recent years,” she says, “is that more and more the cardiology community is recognizing the importance of the kidneys. While cardiology is still ahead of nephrology in terms of clinical trials, we are seeing more and more studies with a primary kidney outcome and a secondary cardiovascular outcome. It’s an exciting time for us to partner with the cardiovascular community because there are many new therapies coming down the pike.”

Race, Ethnicity, and Kidney Disease

Kidney disease disproportionately affects people who are Black or of Hispanic ethnicity and those in lower socioeconomic groups. A lot of the reason is a lack of access to care, risk factors such as diabetes, and a scarcity of options for food. The kidney community is trying to understand how to do better.

The estimated glomerular filtration rate (eGFR) is an important basic way to assess a patient’s kidney function. The formula used to calculate it includes factors such as age, gender, and race, for which the choices are Black or non-Black. The use of racial data is of enough concern that the National Kidney Foundation and the American Society of Nephrology have appointed a task force to look into it and report back.

Chang notes that “there’s been a lot of scrutiny into how we include race in clinical care, including how we calculate the eGFR. Changing the way we calculate it is just the tip of the iceberg, but it may spur more of us to think more deeply about issues of race and ethnicity and medicine.”

Establishing Goals

Goal setting is an important early step for a person in a new position of responsibility. Chang feels that she ascended to become chief of a division that already had a number of strong goals in place, causing her to want “to continue a lot of the things that Glenn prioritized: investing in training fellows and taking care of them and trying to have fellows and faculty in the division who look like the patients we serve. I have other evolving goals, but I want input from faculty in the division on such matters. We have an awesome faculty, and I want them around me forever. I need their help to set the course.”

Adetokunbo Adenike Taiwo, MD, MS

One of those faculty members is clinical assistant professor Adetokunbo Adenike Taiwo, MD, MS, whose path into nephrology was similar to that of her chief. “When I started my residency, I was uncertain what specialty I would choose. Nephrology was not at the top of my list. During my training at the University of Chicago, we took care of a predominantly African American population. The burden of kidney disease in the community made a deep impression on me. Every time I was on call, I admitted several patients with either acute or end stage kidney disease.”

Kidney Transplantation at Stanford

Caring for patients with kidney failure was challenging. Taiwo explains why: “They were often the sickest patients in the hospital. I spent the bulk of my residency taking care of very sick people and trying to get them to feel well enough to return home to their family. Many of these patients were hospitalized frequently with complications related to kidney disease. It just seemed like they never had a great quality of life.”

Getting the sickest patients to life saving transplant is a long, bumpy, uncomfortable path, and it often ends with patients being short of their goal. Dialysis saves them from immediate death, but it takes a long time to get a kidney transplant; the standard waiting time is seven to 10 years in the San Francisco Bay Area. With kidney transplantation, unlike transplantation of other organs where the sickest patients are the ones who are prioritized for transplant, “you have to be fit enough to be transplanted,” says Taiwo. After 10 years on dialysis, the sad reality is that many patients are not healthy enough or have developed complications such as severe vascular disease that make them ineligible for transplantation.

When Taiwo rotated through the kidney transplant service, she encountered a very different set of patients.

“I love asking patients the first time they show up to my clinic

after transplant, ‘What’s different?’ Hearing how much better

they feel makes this field so fulfilling”

“I love asking patients the first time they show up to my clinic

after transplant, ‘What’s different?’ Hearing how much better

they feel makes this field so fulfilling”

Her story continues: “Here I was on a rotation where I was seeing end stage kidney disease patients coming in for follow-up after their kidney transplant, and they looked so well. Knowing that these patients were similar to patients I took care of in the hospital setting really changed my view. I went into medicine to make a difference, to see people get better, to see people go from sick to well. When I saw how much kidney transplantation changed quality of life, it simply blew me away.”

Taking care of transplant patients, she says, “is rewarding every single time. I love asking patients the first time they show up to my clinic after transplant, ‘What’s different?’ Hearing how much better they feel makes this field so fulfilling.”

A Fellow Also Drawn to Transplant

Unlike Taiwo and Chang, Ruth Romero, MD, a second-year fellow, says she “actually wanted to do nephrology since I was in medical school when I learned about electrolytes and fluid balance. It’s very interesting, and it’s challenging to learn it very well.”

Adetokunbo Adenike Taiwo, MD, MS (left) and Ruth Romero, MD (right)

Romero says that she chose “Stanford for my fellowship first because of the faculty. I feel like there is a very good balance here between clinical work and teaching. A lot of the faculty take much of their time to teach us every day when we are rounding. We also have teaching conferences almost every day.”

Romero is also interested in transplant nephrology after having done six months of transplant clinic at Stanford. She says, “We saw transplant patients every one or two weeks; this was pre-COVID. It was such a life-changing experience for everybody. More than half were Latin people, so we had a lot in common because I’m from Ecuador.”

Noting that diabetes and high blood pressure in the U.S. put people at risk of developing kidney disease, she says that there are “certain diseases in the Latin community that also put patients at risk of having end stage renal disease at an early age.”

Beginning in July 2021, Romero will spend a year as a transplant fellow at USC. After that, she says, “it is very likely I’m going back to my home country. I will take all the experiences I had here and bring them back to my native country to practice medicine there.”

Perhaps she heard this advice from the new chief of her division: “This is the thing I tell my fellows: If you approach everything with your best effort and come through when you say you will, opportunities will continue to present themselves to you.”

One Company’s Trash: Nephrology’s Collaboration With Industry in the Fight Against COVID-19

One Company’s Trash: Nephrology’s Collaboration With Industry in the Fight Against COVID-19

It all started with leftovers. Ascend Clinical laboratories was already taking regular (typically monthly) blood samples of its thousands of dialysis patients from centers all around the country when the pandemic hit. And they, like so many others, wanted to help at a time when so many felt helpless.

They were already planning to obtain the capability to test for COVID-19 antibodies but realized they could also potentially test some of the remnant blood they had on hand that they usually throw away. So they reached out to Glenn Chertow, MD, then division chief of nephrology and current Norman S. Coplon Satellite Healthcare professor of nephrology, wondering whether they might be able to help in the fight against COVID-19.

It all started with leftovers. Ascend Clinical laboratories was already taking regular (typically monthly) blood samples of its thousands of dialysis patients from centers all around the country when the pandemic hit. And they, like so many others, wanted to help at a time when so many felt helpless.

They were already planning to obtain the capability to test for COVID-19 antibodies but realized they could also potentially test some of the remnant blood they had on hand that they usually throw away. So they reached out to Glenn Chertow, MD, then division chief of nephrology and current Norman S. Coplon Satellite Healthcare professor of nephrology, wondering whether they might be able to help in the fight against COVID-19.

The Idea

The thought was first broached during a coffee break. Chertow and Ascend CEO Paul Beyer, who’ve known each other for several years, met on a windy afternoon in early spring, when COVID-19 was first starting to surge in New York. “We were basically lamenting how powerless we were and what we could possibly do to contribute to the fight against this virus,” Chertow remembers. Their thoughts first turned to testing, and then to antibody testing, and soon the project was born.

“This is basically a story of two frustrated people, one business person and one doctor, sort of knocking heads together over a cup of coffee,”Chertow explains. Beyer told Chertow about the samples he had access to.

“It clicked in my head, well, this would be an unbiased sample,” Chertow says, “because it’s a population of patients who get their blood drawn on a routine basis because of the nature of their treatment.” If they tested these patients for COVID-19 antibodies, they’d be able to get a fairly clear picture of what the COVID-19 prevalence was in the U.S.

“This is basically a story of two frustrated

people, one businessperson and one doctor,

sort of knocking heads together over a cup of coffee”

“This is basically a story of two frustrated

people, one businessperson and one doctor,

sort of knocking heads together over a cup of coffee”

“It clicked in my head, well, this would be an unbiased sample,” Chertow says, “because it’s a population of patients who get their blood drawn on a routine basis because of the nature of their treatment.” If they tested these patients for COVID-19 antibodies, they’d be able to get a fairly clear picture of what the COVID-19 prevalence was in the U.S.

The idea was promising, but one crucial hurdle remained: how to pay for it. Most dialysis patients are covered by Medicare, which couldn’t cover the costs for a study that didn’t lead to direct patient action. So Beyer volunteered to cover them. “It was an incredibly generous gesture on his part,” Chertow states. He accepted the offer, and they moved forward.

The next step was assembling the team.

The Team

The team was composed of Chertow; Shuchi Anand, MD, assistant professor of nephrology; biostatisticians Maria Montez-Rath, PhD, senior research engineer of nephrology, and Jialin Han, MS; and epidemiologist Julie Parsonnet, MD, George DeForest Barnett professor of medicine. They decided to study the remnant blood for the presence of COVID-19 antibodies (also known as “seroprevalence”) and then analyze the anonymized data based on geographical region, ethnicity, and other data points. The process started in June 2020, testing was done throughout the month of July, and initial data were submitted in mid-August, a blisteringly fast pace for this kind of research.

Maria Montez-Rath, PhD

The Team

Nearly all of them worked from home. One of the greatest challenges, Anand explains, came from an overall positive: They had almost too much data coming at them too fast. “We just really had to work hard to interpret it and present it in a rigorous manner,” she says. “And our team was really holding itself to a high standard to do that well.”

As the principal biostatistician of the group, Montez-Rath both planned and designed the data analysis, working “many hours” on the “very intense” project. She adds, “In a pandemic, all data becomes outdated very quickly and new knowledge is created at a very fast pace, which makes it even harder to maintain high-quality work. Given that all my other projects didn’t stop when the pandemic started, it resulted in many more hours of work (including nights and weekends) beyond what I would normally do.”

Still, she remembers the work fondly. “I immediately realized that the project was going to have a really high impact,” she says. Her enthusiasm for her work kept her going. As she explains, “I have my dream job: working closely with people in various projects that ideally have an impact on people. I feel that what I do is useful to patients and to the betterment of the world.”

Han, a biostatistician hired at Stanford in 2018, echoes Montez-Rath’s passion for meaningful work: “It’s always interested me that my work could improve people’s quality of life,” he says. He heard about the project in June 2020, when Montez-Rath realized there was too much statistical work to do all by herself. He describes the hectic pace of the process this way: “We met frequently to summarize the research questions and the analysis plan. It all came really fast, especially since at that time there was no report about national seroprevalence at all. The idea was if we want to do this, we have to do it fast.”

And he means fast—some days he met the team at 7 a.m. to discuss a problem and then again at 5 p.m. that same day to track the progress. He describes the work as “really intense and time sensitive,” but adds, “We understood the importance of this study, so we wanted to do the best we could.” His role included data preparation, data mining, data analysis, and output generation.

Parsonnet was brought on board for her epidemiological expertise, giving opinions on study design and meeting regularly with the team to “discuss what the data showed and go over it and review what it meant and how we interpreted it, given the world around us.” It was her first collaboration with this team and she found it to be “just such a pleasure.”

Shuchi Anand, MD

The Study

Initially, Anand recalls, “it was important to understand in real time what was happening with the epidemic.” Ascend’s data drew from 46 states and a third of all counties in the U.S., spread from coast to coast.

Forty percent of the samples were from patients 65 and older, and since patients on dialysis are often from disproportionately disadvantaged populations, racial and ethnic minorities and people from poorer neighborhoods were actually overrepresented in the population of the study. “That was great,” Anand explains, “because those groups are often the most vulnerable to SARS-CoV-2 but are so hard to reach via a door-to-door survey.”

The researchers were also able to use the results from this population to extrapolate. “Our main goal was not just to provide a sample that was representative of the Ascend dialysis population but also to then analyze the data so it could represent both the overall dialysis population and the general adult population of the U.S.,” Montez-Rath states.

The Results

The results came quickly: Regional and ethnic differences made a significant impact on the prevalence of COVID-19 antibodies (and, therefore, the rates of COVID-19 infection in various communities). The intense outbreak at the time was in New York City, and seroprevalence was up to approximately 25% in New York City at the time of the study, compared with approximately 2% to 5%in the rest of the U.S.

The team also found that people who were living in minority neighborhoods or self-identified as being minorities were at an approximately two-to threefold higher risk at that time for seroprevalence and infection. As Anand concludes, “It wasn’t just that they were getting COVID-19 at the same rate and dying more. It was also that they were getting more COVID-19.”

And within these results, they were able to extrapolate to larger regions, estimating that seroprevalence in the U.S. at the time would be somewhere near 9% for the U.S. adult population. This estimate, incidentally, ended up being remarkably accurate—at the time the Stanford study was published, the Centers for Disease Control and Prevention was conducting an independent analysis that hadn’t yet been completed, but when it was published in August, their estimates were “very similar.” Initially, Anand recalls, “it was important to understand in real time what was happening with the epidemic.” Ascend’s data drew from 46 states and a third of all counties in the U.S., spread from coast to coast.

Working With Industry

Anand called working with Ascend “mutually inspiring” because the company displayed an incredibly compassionate desire to help in any way. “They understood the true potential of what they had, and we really understood their willingness and capabilities as well,” Anand says.

Montez-Rath agrees: “What surprised me the most about this project was the people involved, especially Ascend’s participation.” She calls this industry/academy collaboration “something to be celebrated.”

Parsonnet was “very happy about how great the renal dialysis units were about wanting to participate.” She adds, “It’s nice to see these dialysis centers really care about doing the right thing for their patients. It makes me feel good about the world.”

Chertow concludes, “Academy and industry partnerships sometimes work!”

“We’re not developing vaccines, we’re not the people doing

the phenomenal earth-shattering stuff, but we have helped to

inform the understanding of where the pandemic was raging, how

it’s been spreading, how it’s been disproportionately affecting

persons of color and other disadvantaged populations. We’re

helping, little by little, in our own way”

“We’re not developing vaccines, we’re not the people doing

the phenomenal earth-shattering stuff, but we have helped to

inform the understanding of where the pandemic was raging, how

it’s been spreading, how it’s been disproportionately affecting

persons of color and other disadvantaged populations. We’re

helping, little by little, in our own way”

Future Studies

The pandemic will eventually end, but studies using this remnant blood are continuing, and projects with this population will continue in the future too. The Stanford team is examining various aspects of dialysis and COVID-19, including studying transmission risks and infection mitigation at dialysis centers and looking to the possibility of future seasonal COVID-19 infections and how they will affect dialysis patients, who often do worse during winter months.

They’re also working on a repeat cross section to try to get a sense of seroprevalence in the U.S. a year into the pandemic, particularly before the vaccine rollout—information that Anand calls “critical.” In addition, they have both vaccine response and vaccine acceptability studies in dialysis patients in the works, including a vaccine acceptability survey among dialysis patients led by nephrology fellow Pablo Garcia, MD.

And their work has even helped inspire other universities and dialysis centers. “I know several dialysis networks are looking at vaccine response in dialysis patients,” Anand says. “They may have chosen to do that independently, but hopefully we gave them sort of a road map for how to do it as well. Which is great, because we want our patients to be protected, and we want our colleagues to study that and improve ways to make that happen.”

Part of the Fight

Chertow concludes, “I think in our own way we’ve contributed to the fight against COVID-19. We’re not developing vaccines, we’re not the people doing the phenomenal earth-shattering stuff, but we have helped to inform the understanding of where the pandemic was raging, how it’s been spreading, how it’s been disproportionately affecting persons of color and other disadvantaged populations. We’re helping, little by little, in our own way.”

   Jialin Han, MS

Working Within and Among Divisions

The team members also enjoyed working among different divisions at Stanford. Han appreciated the learning opportunities the work gave him. “One of the amazing parts about being a biostatistician is that I can work with people from different backgrounds and disciplines, and I really enjoy it,” he says.

Anand loved working with Parsonnet. “She’s one of the world’s experts on epidemiology in general, and just getting her perspective on contextualization for how this work would be important and why it would be important was really great,” she says.

And Parsonnet also loved the team. “Shuchi is amazing, really sharp and hardworking and innovative and really tremendous,” she says. “And Maria is just terrific in thinking about ways to look at the data. I think of it as their work, and it was an honor for me to be able to participate in any way.”

Chertow, too, was filled with enthusiasm for the team, from Ascend and all across Stanford. “It’s been a very meaningful and satisfying collaboration for me,” he states. “The greatest gift to a teacher is when his or her student proves to be 10 times smarter than he is. It’s sort of like planting a seed and watching a grove of fruit-bearing trees grow. And that’s what working with people like Shuchi and Maria and Julie has been like.”

Systemic Sclerosis: A Rare Disease That Requires Several Specialists

Systemic Sclerosis: A Rare Disease That Requires Several Specialists

Systemic Sclerosis: A Rare Disease That Requires Several Specialists

For unknown reasons, autoimmune diseases attack the body insidiously, often wreaking havoc and causing immense disruption to patients’ lives. There are more than 100 autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.

Systemic sclerosis is another autoimmune disease, characterized by widespread fibrosis (replacement of normal tissue with scar tissue), vasculopathy (affecting blood vessels), and inflammation. It is a particular clinical interest of Lorinda Chung, MD, MS, professor of immunology and rheumatology and dermatology.

Systemic sclerosis is a very rare disease, less common than lupus or rheumatoid arthritis, but more common than dermatomyositis. There is a female predominance (4–5:1); however, men tend to have a worse prognosis. It typically presents in patients from their 30s to their 60s. African American patients definitely have a poorer prognosis than Caucasians, and Asians with the disease do as poorly as African Americans, as was demonstrated in Chung’s recent publication about racial disparities in systemic sclerosis based on the Kaiser Permanente Northern California database.

How Patients With Systemic Sclerosis Present

Chung describes the different manifestations of systemic sclerosis: “There are two major subtypes of systemic sclerosis: diffuse cutaneous and limited cutaneous. The subtypes are purely based on the extent of skin tightening that the patient presents with. Patients with diffuse cutaneous involvement have widespread skin tightening as well as higher likelihood of early and severe internal organ involvement, including the lungs, heart, and kidneys, as well as the muscles and joints.”

One very common feature of systemic sclerosis is Raynaud’s disease, a rare disease that reduces blood flow to the fingers and toes, causing them to turn white and become numb, which occurs in 90% of patients. Patients with the second subtype of systemic sclerosis, the limited subtype, frequently suffer from Raynaud’s and vascular phenomena like digital ulcers. These patients often live for a while without their internal organs being affected but have a higher likelihood of gastrointestinal (GI) and lung involvement later in their disease. Chung explains that “they can get severe dysmotility of their GI tract and also develop pulmonary hypertension. There are some good treatments for pulmonary hypertension, but we really struggle with treatment of the GI manifestations.”

A Special Clinic

There is a unique multidisciplinary clinic every Monday afternoon in Redwood City that focuses on the dermatologic and immunologic aspects of systemic sclerosis. Professor of dermatology David Fiorentino, MD, PhD, helped found the clinic close to 20 years ago because, as he says, “I saw a huge gap in the care of some patients if different doctors weren’t communicating in real time regarding patient care.”

Having patients seen simultaneously by both a dermatologist and a rheumatologist solved that, and the clinic is so successful, says Fiorentino, that “access is a big problem. We’re always scheduling a minimum of three to four months in advance. That is literally our biggest challenge, and it has been almost since the beginning of the clinic.”

The process that patients follow when they attend this clinic is unusual in several ways. For one thing, says Fiorentino, “we don’t see anyone in the clinic whose medical information has not been personally reviewed by either Dr. Chung or me or both. Patients carry around misdiagnoses of rheumatic diseases quite commonly, and clinic appointments are so precious that we need to make sure the appropriate patients are seen in our clinic.”

When patients arrive, they are assigned to a room where their vital signs are recorded and their medications are reconciled. They also change into a gown, which is unusual for rheumatology patients but not for dermatology patients because the skin needs to be examined. Then they are seen by a rheumatology fellow and a dermatology resident together, who go over the history, followed by targeted physical exams. The rheumatology fellow does a general medical examination with a focus on the joints and muscles. The dermatology resident assesses the skin to see how tight it is and to look for other specific skin markers of scleroderma.

After the trainees report their findings to Chung and Fiorentino and they come up with a reasonable plan, all four physicians go into the patient’s room, where, Fiorentino says, “we confirm important parts of the history with the patient, briefly examine the skin, and point out to trainees any unusual findings that might be helpful either diagnostically or prognostically. Patients often have a list of questions, as they’ve waited three or four months, and they’ve often traveled very far for the appointment.”

“At the end of the visit,” Fiorentino says, “Dr. Chung and I always bring up that we do research in the disease. We explain why it’s important to study actual patients and that complex rheumatic diseases are poorly modeled in the laboratory. We stress how rare their disease is and that this is an opportunity to turn the pain and suffering of their disease into something profoundly important and positive. When the patients better understand this perspective, 95% of them agree to be part of our research cohort and donate tissue.”

Lori Chung, MD (second from left), consults with (from left) resident Steven Mason Ronilo, MD; professor of dermatology David Fiorentino, MD; and resident Lucy Liu, MD

Internal Organ Involvement

Treatment for systemic sclerosis depends on what organ systems are involved. There’s quite a bit of data supporting the use of CellCept, an anti-rejection medication, to slow the progression of skin tightening; methotrexate can also be used. Chung uses CellCept more frequently because it helps both the skin and the lungs, whereas methotrexate doesn’t tend to help the lungs. Chung says that “clinical trials primarily target the skin, the lungs (in terms of interstitial lung disease and pulmonary hypertension), and the vascular system in terms of Raynaud’s phenomenon and digital ulcers. Most clinical trials are focused on those aspects of the disease because they’ve been best studied.”

There are many treatment choices for Raynaud’s disease, including drugs like calcium channel blockers that improve blood flow and other vasodilating therapies that are approved for pulmonary hypertension, such as sildenafil.

Chung says this is an exciting time to be involved in clinical trials for systemic sclerosis. “We now have two drugs approved for scleroderma lung disease: An antifibrotic drug called nintedanib was approved in 2019, and the anti-interleukin-6 biologic tocilizumab received FDA approval in March 2021. Stanford was involved in the clinical trials for both of these agents.”

Because of the extent of possible internal organ involvement in systemic sclerosis, Chung points out, there is a critical need for collaborations across the Department of Medicine to care for these patients. She explains their roles: “We work closely with pulmonologists for both interstitial lung disease and pulmonary hypertension in our patients. We also work closely with GI and cardiology. Because we have patients who have severe disease in their blood vessels, we work with a hand surgeon who does sympathectomies on these patients.”

“We stress how rare their disease is and that

this is an opportunity to turn the pain and

suffering of their disease into something profoundly

important and positive”

“We stress how rare their disease is and that

this is an opportunity to turn the pain and

suffering of their disease into something profoundly

important and positive”

For some patients with end-stage interstitial lung disease and/or pulmonary hypertension, lung transplant is an option. For such patients, says Chung, “we engage closely with colleagues from the division of pulmonary, allergy & critical care medicine. Because of the significant GI issues, lung transplants in patients with systemic sclerosis can be complicated by aspiration pneumonia, and therefore patients must meet certain criteria to be eligible for this procedure. Hematopoietic stem cell transplantation is reserved for patients with severe progressive systemic sclerosis. We have established a protocol in conjunction with colleagues from the blood and marrow transplantation & cellular therapy division, and in March 2021 we transplanted our second patient with systemic sclerosis.”

While systemic sclerosis is not exactly a genetic disease, there can be some predisposition. “We think there has to be some sort of trigger for the disease to actually come on,” says Chung, “and one potential trigger is cancer. We think there is immune surveillance going on in the body, where the body is trying to shut down the cancer, which is sometimes successful and sometimes not. That’s when we can see that there’s a cancer associated with the onset of systemic sclerosis or dermatomyositis.”

Chung continues, “Certain autoantibodies are associated with a higher risk of cancer in systemic sclerosis or dermatomyositis. This makes us believe that your immune cells are reacting to an antigen that is similar to a cancer antigen, and that develops antibodies in reaction to potential cancer. The autoantibody associated with cancer in systemic sclerosis is RNA polymerase III. These patients tend to have really bad skin tightening and are also at risk for developing kidney involvement, called scleroderma renal crisis. ACE inhibitors are the mainstay of treatment for scleroderma renal crisis and have greatly reduced the number of patients who have to go on dialysis.”

While systemic sclerosis is both difficult to diagnose and difficult to treat, involving such a vast assemblage of experts across the Department of Medicine improves both the access and the outcomes of patients at Stanford.

Fine-Tuning Medications for Stronger Veteran Hearts

Fine-Tuning Medications for Stronger Veteran Hearts

Fine-Tuning Medications for Stronger Veteran Hearts

Cardiologists have learned over the past 30 years that patients with heart failure benefit the most from taking four classes of medications at the optimal dosages. Despite this, a third or more of patients living with this disease are not prescribed these evidence-based therapies at all, and many others receive prescriptions at suboptimal dosages. It’s a huge problem, even among the heart failure patients seen at the Veterans Affairs (VA) Palo Alto Health Care System, where a minority of heart failure patients take the fully recommended doses of these medications known to improve health and lengthen lives.

To try to turn that around, a collaboration between Stanford and the Palo Alto VA beginning in late 2019 tested a new approach to have pharmacists upwardly adjust, or titrate, patients’ doses for maximum benefit. The population health project brings together an interdisciplinary team of cardiologists, primary care physicians (PCPs), nurses, heart failure researchers, and pharmacists. Veterans in the program work with clinical pharmacists over several visits and calls to get to their optimal dosages.

“We get to leverage Stanford researchers’ expertise on new, cutting-edge interventions to more quickly implement evidenced-based treatments” at the VA, says Rhonda Hamilton, MD, MPH, clinical assistant professor of primary care and population health and general medicine clinic section chief at the Palo Alto VA, who is overseeing the project’s expansion at the Palo Alto clinic site. Under the mentorship of Nazima Allaudeen, MD, clinical assistant professor and director of quality improvement for inpatient medicine at the Palo Alto VA, Justin Slade, MD, led the pilot project while he was a cardiology postresident at Stanford as well as the Physician Scholar for Quality and Safety at the Palo Alto VA. The pilot project focused on the Major General William H. Gourley VA-DoD Outpatient Clinic, typically known as the Monterey VA site.

Maryn Yamamoto, pharmacist; Rhonda Hamilton, MD; Jessica Tran, pharmacist; Lauren Hamilton, data analyst

After just five months of the pilot project, patients on average significantly increased their dosages of both beta-blockers, which slow heart rate, and ACE inhibitor–like drugs, which lower blood pressure. In addition, the numbers of patients at or above 50% of the recommended doses for both drugs have steadily increased since the program began at the VA’s Monterey site. Due to that success, the program was expanded to three more Palo Alto VA sites.

“In the VA system, we have a responsibility not just to fix patients up in the hospital and send them home, but also to keep them healthy for the rest of their lives,” says Slade.

Undertreated Hearts

Heart failure affects 6.2 million adults in the U.S. and nearly 2,000 people across the Palo Alto VA system.

One of the first lines of treatment is to put patients on four different classes of medications. Taken together, these drugs work to reverse the hormonal signals in response to heart failure that tell the heart to work harder, and they reduce pressures in the heart to allow heart function to stabilize and get stronger.

Slade explains that cardiologists have long known that the optimal dosages of the four recommended drug treatments help people live better and longer with heart failure. “But the real challenge is getting those treatments to people in a more consistent, reliable way,” says Allaudeen.

Alex Sandhu, MD, MS

There are many barriers to optimal dosing, including 30-minute clinic appointment windows, during which a cardiologist or PCP must cover previous and current health issues, physician concerns, patient concerns, and a review of the 10 or more medications that veterans on average take, says Hamilton.

Alex Sandhu, MD, MS, instructor of cardiovascular medicine and the heart failure researcher advising the project, says that physician inertia can be another barrier when a patient’s condition appears stable. “Even among stable patients, the risk of deteriorating and getting sicker is substantial,” he says.

By harnessing data from a new VA heart-failure patient dashboard, the team can identify which patients are taking less than the recommended doses of beta-blockers and ACE inhibitor–like drugs. “The dashboard is also an important tool in addressing health care disparities,” says Allaudeen, because it can identify patients who are not coming in as frequently by their data, rather than relying solely on physician referrals.

Among approximately 1,400 patients with heart failure, the team found that fewer than half were taking the drugs at a dosage that was at least 50% of the recommended dosage. (They use 50% or greater as the mark for the recommended dosage because not all patients can tolerate 100%.)

Because heart failure is progressive and the drugs’ effects are additive, getting patients to the highest tolerable doses is key: “The maximum tolerated dose is where these patients will get the most benefit,” says Slade.

Problem-solving Pharmacists

To titrate to that maximum dose, however, normally requires visits to the doctor’s office every two weeks for several months. Very few physicians have the bandwidth to handle that many visits, and many VA patients live far away or lack transportation.

Instead, the team tested the new approach with clinic pharmacists handling these iterative visits, following a cardiologist’s protocol to titrate doses and do follow-up appointments by phone or video call. During the five months of the study, which concluded in April 2020, patients on average improved their beta-blocker doses from 19% to 35% of the recommended dose, and their ACE inhibitor–like doses increased from 52% to 81% of the recommended dose.

“We want our patients to be on the best medical

therapy for heart failure. Every month or year

that goes by that a patient isn’t, that’s a missed opportunity”

“We want our patients to be on the best medical

therapy for heart failure. Every month or year

that goes by that a patient isn’t, that’s a missed opportunity”

“The pilot was definitely a great success to demonstrate that pharmacists were able to successfully increase patients’ doses and safely improve treatment,” says Sandhu. Importantly, there were no safety events or emergency room visits associated with the dosage changes. Sandhu will continue to advise the expanded project on incorporating newer therapies and formally evaluating the program’s impact.

Allaudeen, who cares for patients at the end stages of heart failure in the hospital, says that projects like this are a big win for everyone—for the facility in lowering costs, for the care teams who can treat patients more effectively, and for the patients themselves. The next step is to expand the program to all eight VA clinic sites, with programs currently started in the San Jose, Livermore, and Palo Alto sites.

Allaudeen feels an urgency to get there: “We want our patients to be on the best medical therapy for heart failure. Every month or year that goes by that a patient isn’t, that’s a missed opportunity.”

Taking Racial Disparities to Heart

Rhonda Hamilton was looking for ways to make a real difference in Black and Latinx VA patients’ lives, and she saw an opportunity after the death of George Floyd and the national resurgence of the Black Lives Matter movement.

“I wanted to leverage my leadership position to help with the health care disparities facing Black and Latinx patients in our medical care,” says Hamilton. So she formed a VA committee, and with her teenage daughter Lauren as their research assistant, they found striking results for heart failure: In the United States, “Black patients with heart failure symptoms were far less likely to be on the recommended doses of medications compared to their white counterparts,” says Hamilton.

The new approach to optimizing heart failure medications brings the added bonus of addressing this large racial health care disparity.

“Studies like this one save lives” in tangible ways, says Hamilton. Through her research on health disparities, Hamilton’s daughter Lauren also came to a striking conclusion: Interventions that better meet the needs of Black patients help all patients. And that, Hamilton says, makes the program a win for all veterans and their doctors.

Personal Experience Motivates Tian Zhang’s Work With AML Patients

Personal Experience Motivates Tian Zhang’s Work With AML Patients

It would be enough for a young physician-scientist to tackle the challenge of an extremely aggressive disease like acute myeloid leukemia (AML) while setting up a translational research program, but Tian Zhang, MD, PhD, is doing all that and more.

The new assistant professor of hematology has a young child with an exceptionally rare genetic disorder, but she has found a way for her son’s medical condition to motivate her in her work.

Zhang’s story begins after extensive basic science training, which led to a doctorate in cellular and molecular immunology. A desire to become a physician-scientist prompted her to attend medical school after earning her PhD. During a clinical rotation in year three she became aware of AML, which she says is “the most aggressive and most common kind of acute leukemia in the elderly.”

Zhang’s work with an AML patient showed her firsthand how dramatically the disease presents, as well as its very poor prognosis in most patients, with few treatment options. As part of a huge medical team following a complicated care plan for the AML patient, she was drawn to the disease both intellectually and emotionally, and she chose it for her clinical focus.

She didn’t know it at the time, but the bedside observations she made during both medical school and internal medicine residency would be of great value after she came to Stanford in 2014 for a hematology/oncology fellowship. As a fellow, she witnessed the work that hematology division chief Ravi Majeti, MD, PhD, was doing in the molecular characterization and therapeutic targeting of leukemia stem cells in AML.

“As a translational physician-scientist, I picked Dr. Majeti’s lab to do my postdoc work, and that’s where I took my bedside observations and created a preclinical model so we could study how an experimental treatment would affect human AML cells that were injected into mice,” she says.

Tian Zhang, MD, PhD, with her family

Motivated by Firsthand Experience

While in the midst of her postdoctoral work in Majeti’s lab, Zhang’s life took a dramatic turn when she learned that Isaac, her 4-month-old son, had spinal muscular atrophy (SMA) type 1 (also called Werdnig-Hoffmann disease). Children with SMA type 1, which is characterized by muscle weakness, are not expected to survive past early childhood.

“Obviously that was devastating,” Zhang says after a heavy sigh.

“People with the best of intentions gave me a lot of advice. Most said I should stop working and take care of my 2-year-old daughter and my sick baby, but I took a different track and immersed myself in my work.”

Zhang questioned whether that was a coping mechanism, but she believes it was more likely something else.

“I wasn’t much of a drug developer, to be

honest, before all of this happened to Isaac, but

when I personally witnessed what could come from

the type of research I was performing, I recommitted

myself to working on a rare disease”

“I wasn’t much of a drug developer, to be

honest, before all of this happened to Isaac, but

when I personally witnessed what could come from

the type of research I was performing, I recommitted

myself to working on a rare disease”

Groundbreaking Drugs

What happened—and what would have made a lifesaving difference to so many other babies before Isaac—was that he received three first-in-human drugs from the time he was 4 months old.

Just a year before Isaac’s birth, there was no treatment at all for SMA type 1. Then, the drug Spinraza was approved, and specialists prescribed it for Isaac to keep the disease from progressing.

The following year, Isaac received another breakthrough treatment—the first gene-replacement therapy to correct a genetic deficiency that was lethal in babies—which improved his condition.

And in August 2020, he received a third FDA-approved treatment, risdiplam, for SMA type 1, which furthered his improvement.

“I am a scientist at heart, and I know all the details of how long it takes for a drug to become available. So when I saw firsthand the direct benefit that Isaac received from people like me who were working on rare diseases and invested in drug development, it actually motivated me.

“I wasn’t much of a drug developer, to be honest, before all of this happened to Isaac, but when I personally witnessed what could come from the type of research I was performing, I recommitted myself to working on a rare disease,” Zhang says.

Investigator-Initiated Trial

Success from her preliminary research led her to suggest repurposing the drug enasidenib for use in a variety of blood disorders. For more than a year, she offered her concept to pharmaceutical companies before she reached an agreement with Celgene for the Bristol-Myers Squibb subsidiary to fund her investigator-initiated trial.

Typically a pharmaceutical company develops its own drugs, and the company will approach an institution like Stanford to perform a study because of the drug’s promise for patients with a particular disease. This is known as a sponsored trial.

“We have many sponsored trials in the division of hematology, but we didn’t have many of these home-grown or home-investigated projects like mine that clearly could have clinical benefit,” she explains.

AML Translational Research Program

Zhang, who was appointed assistant professor of hematology in March 2020, is now working to establish an independent research program focused on translational research in AML. She’s collaborating closely with Majeti and Gabriel Mannis, MD, another AML physician and assistant professor of hematology, to link the lab and the clinic.

“The goal of this translational program in AML is to bridge the gap between basic laboratory scientific research and clinical trials, but equally importantly to take observations from the clinic back to the lab. A major focus will be on developing investigator-initiated trials at Stanford,” Majeti says.

Leaders of the translational program see the chance to create a better pathway for scientists who work on the bench, allowing them to engage with clinicians who are on the front lines of patient care. The program should allow them to exchange ideas for new research projects that can be developed with the eventual aim of translating them back into the clinic.

As a physician-scientist who’s been working in the Majeti lab as well as taking care of patients both in the clinic and on the inpatient side, Zhang is uniquely positioned to help both sides.

“Tian is the perfect person to head up our AML translational research program, as she is accomplished in both laboratory research and clinical care of AML patients,” says Majeti. “She knows exactly how basic investigation can be applied in the clinic and equally how clinical observations can be explored in the lab.”

While Zhang is building her program for translational science with an initial focus on AML, the broader goal is to expand into other diseases. “In fact, as we develop the AML program, we are building infrastructure that can be applied to research for other kinds of blood disorders,” she says.

“I’ve become a huge advocate for drug development because I now realize the benefit that patients can derive from new treatments that are coming up through translational research,” she adds.

How is Isaac today?

“Now he is 3 and doing things that I never imagined he would do,” she says.